Real-world data showed that upfront autologous hematopoietic stem cell transplantation (AHCT) for treatment of multiple myeloma (MM) was less frequently used in older patients and patients with comorbidities, according to a study published in Bone Marrow Transplant.
“Supported by clinical trial proven survival benefit, clinical guidelines recommend upfront AHCT for eligible [patients with] MM,” wrote the study authors. “However, reported real-world utilization is lower than expected.”
Evaluating AHCT Utilization
The researchers used the Australian/New Zealand Myeloma and Related Disease Registry to identify 982 patients treated for MM between June 2012 and May 2020. Overall, 298 patients were aged older than 65 years. The rate of AHCT usage was 76% overall. More patients aged <65 years received AHCT compared to patients aged ≥65 years (83% vs. 61%). AHCT was a front-line therapy for 67% of patients.
Patients who did not receive stem cell transplant tended to be older (P<0.001) and had higher rates of comorbidities compared to patients who underwent AHCT. Rates of cardiac disease (16.9% vs. 5.4%), diabetes (19.1% vs. 7.0%), and renal dysfunction (median estimated glomerular filtration rate, 68 vs. 80) were higher for those without versus with AHCT (P<0.001). High-risk MM was also more common in patients who did not undergo transplant (37%) than those who did (26%).
Survival Benefits of Stem Cell Transplant
The use of AHCT led to longer progression-free survival (PFS, 45.3 months) and overall survival (OS, not reached) compared to other therapies (PFS, 35.2 months; OS, 64.0 months). These benefits did not differ by patient age. Among patients aged >65 years, median PFS was 45.3 months and median OS was not reached, compared to 37.7 months and 68.2 months, respectively, in the non-AHCT group. In patients aged 65–70 years, median PFS in the AHCT cohort compared with the non-AHCT cohort was 46.7 months versus 29.2 months (P<0.001), and median OS was 76.9 months versus 55.6 months, respectively (P=0.005).
In conclusion, the authors wrote, “This large, real-world cohort reaffirms AHCT survival benefit, including in ‘older’ patients necessitating well-designed studies evaluating AHCT in ‘older’ MM to inform evidence-based patient selection.”
New article: Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR) https://t.co/ktU3R2vg08 #MMSM #MultipleMyeloma #hematology pic.twitter.com/iBIRn4grFd
— Paperbirds_Hematology (@PaperbirdsM) May 20, 2021